Cancer – AAML1421: Phase 1/2 Study of CPX-351 Alone Followed By Fludarabine, Cytarabine and G-CSF for Children with Relapsed Acute Myeloid Leukemia
Condition or Therapy:
Cancer and Blood Disorders
Study Number: AAML1421
What is the goal of this study?
This study is looking at how well a patient with relapsed or refractory Acute Myeloid Leukemia (AML) responds when given liposome-encapsulated daunorubicin-cytarabine with fludarabine phosphate, cytarabine and filgrastim.
Who can join the study?
This study may be a good fit for children and young adults who:
- are 1 to 21 years old, and
- have had relapsed or refractory AML.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.